Login to Your Account



Returns Pain Device Rights to Durect

Endo Withdraws Frova Migraine Application

By Donna Young


Wednesday, April 9, 2008
After receiving a not approvable letter last fall, Endo Pharmaceuticals Inc. said it has decided to withdraw its supplemental new drug application for its migraine headache drug Frova as a short-term preventive treatment for menstrual migraines. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription